89zr-bevacizumab
mAbexperimentalImaging agent
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Mar 31, 2010 (NCT00991978)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Vascular endothelial growth factor receptor 1BINDING AGENT
FLT1 binding agent
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 89-zircon
Oral
No
Parenteral
No
Topical
No
Also known as
- 89zr-bevacizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04813913 | Phase 4 | May 5, 2019 | Rouen Normandy University |
| NCT01894451 | Early Phase 1 (Phase 1) | Jun 1, 2015 | Harvard University, National Cancer Institute (NCI) |
| NCT01859234 | N/A | May 1, 2013 | University of Groningen |
| NCT00991978 | Early Phase 1 (Phase 1) | Mar 31, 2010 | University of Groningen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Groningen | Academic/Hospital | 2 | 2 | 2 | 2010 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
| Rouen Normandy University | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1